Multiple myeloma in the elderly patients:From frailty assessment to progress in Immunotherapy

被引：1
|
作者：
Facon, T. [1 ]
Manier, S. [1 ]
机构：
[1] CHU Lille, Hop Claude Huriez, Serv dhematol, 2 Ave Oscar Lambret, F-59037 Lille, France
来源：
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE | 2022年 / 206卷 / 08期
关键词：
Multiple myeloma; Drug Therapy; Therapy; Immunotherapy; Oncogeriatry; Frail elderly patient; STEM-CELL TRANSPLANTATION; OPEN-LABEL; GERIATRIC ASSESSMENT; DEXAMETHASONE; BORTEZOMIB; MELPHALAN; LENALIDOMIDE; PREDNISONE; PHASE-3; DARATUMUMAB;
D O I：
10.1016/j.banm.2022.07.006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple myeloma is primarily a disease of the elderly patients. Geriatric aspects have been poorly investigated until recently. Frailty assessment is now more frequent and will be useful in the context of significant and sustained therapeutic progress. The recent emergence of immunotherapy with CD38 monoclonal antibodies and upcoming immuno-oncology drugs such as bispecific antibodies will lead to additional progress. The applicability of these complex molecules to elderly and frail patients is a key clinical question.(c) 2022 l'Academie nationale de medecine. Published by Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：966 / 972
页数：7
相关论文
共 50 条
  • [1] Three Drug Combinations in the Treatment of Fit Elderly Multiple Myeloma Patients
    Gardeney, Helene
    Bobin, Arthur
    Gruchet, Cecile
    Sabirou, Florence
    Levy, Anthony
    Nsiala, Laly
    Cailly, Laura
    Tomowiak, Cecile
    Torregrosa, Jose
    Moya, Niels
    Hulin, Cyrille
    Leleu, Xavier
    Guidez, Stephanie
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (11) : 1 - 15
  • [2] Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij, Christie P. M.
    Korst, Charlotte L. B. M.
    van de Donk, Niels W. C. J.
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (06) : 664 - 671
  • [3] Immunotherapy with Antibodies in Multiple Myeloma: Monoclonals, Bispecifics, and Immunoconjugates
    Verkleij, Christie P. M.
    Bruins, Wassilis S. C.
    Zweegman, Sonja
    van de Donk, Niels W. C. J.
    HEMATO, 2021, 2 (01): : 116 - 130
  • [4] Immunotherapy in multiple myeloma
    Hutchins, Irene M.
    Schachter, Levanto G.
    Mahindra, Anuj K.
    TRANSLATIONAL CANCER RESEARCH, 2017, 6 (01) : 109 - 116
  • [5] Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab
    Afifi, Salma
    Michael, Angela
    Lesokhin, Alexander
    ANNALS OF PHARMACOTHERAPY, 2016, 50 (07) : 555 - 568
  • [6] The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma
    Bobin, Arthur
    Gardeney, Helene
    Sabirou, Florence
    Gruchet, Cecile
    Levy, Anthony
    Nsiala, Laly
    Cailly, Laura
    Tomowiak, Cecile
    Torregrosa, Jose
    Guidez, Stephanie
    Leleu, Xavier
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [7] Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy
    Rocchi, Serena
    Zannetti, Beatrice Anna
    Marconi, Giovanni
    Lanza, Francesco
    CELLS, 2024, 13 (10)
  • [8] Visualizing immunotherapy for multiple myeloma worldwide from 2013 to 2023: A bibliometric analysis
    Li, Jinqiao
    Li, Xiaoxia
    Fu, Yueyue
    Meng, Hongbin
    Xu, Dan
    Hou, Wenyi
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [9] Diagnostic and Therapeutic Challenges in the Management of Intermediate and Frail Elderly Multiple Myeloma Patients
    Bonello, Francesca
    Boccadoro, Mario
    Larocca, Alessandra
    CANCERS, 2020, 12 (11) : 1 - 17
  • [10] IMMUNOTHERAPY IN MULTIPLE MYELOMA
    Gleason, Charise
    Catamero, Donna D.
    SEMINARS IN ONCOLOGY NURSING, 2017, 33 (03) : 292 - 298
12345